LOGIN  |  REGISTER
Recursion
Astria Therapeutics

DocGo to Announce Fourth Quarter and Full-Year 2022 Results on Monday, March 13

February 21, 2023 | Last Trade: US$2.12 0.07 -3.20

NEW YORK / Feb 21, 2023 / Business Wire / DocGo, a leading provider of last-mile mobile health services (Nasdaq: DCGO), today announced that the company will report results for the fourth quarter and full-year ended December 31, 2022, after the markets close on Monday, March 13th. Management will host a conference call for analysts and investors at 5:00pm ET on that day.

Conference call and webcast details:

Monday, March 13th, 5:00pm ET
1-877-407-0784 (U.S.)
1-201-689-8560 (international)
Conference ID: 13736245

To access the Call me™ feature, which avoids the need to wait for an operator, click here.

The webcast can be accessed under Events on the Investors section of the company’s website, https://ir.docgo.com/.

About DocGo

DocGo is a leading provider of last-mile mobile care services. DocGo is disrupting the traditional four-wall healthcare system by providing high quality, highly affordable care to patients where and when they need it. DocGo's innovative technology and dedicated field staff of certified health professionals elevate the quality of patient care and drive business efficiencies for facilities, hospital networks, and health insurance providers. With Mobile Health, DocGo empowers the full promise and potential of telehealth by facilitating healthcare treatment, in tandem with a remote physician, in the comfort of a patient's home or workplace. Together with DocGo's integrated Ambulnz medical transport services, DocGo is bridging the gap between physical and virtual care. For more information, please visit www.docgo.com.

Astria Therapeutics

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page